LONDON – Brexit finally becomes a reality at midnight central European time on Jan. 31, but for the life sciences industry uncertainty continues, as the U.K. enters an 11-month transition phase during which the terms of its future relationship with the EU must be negotiated. Read More
Vertex Pharmaceuticals Inc. brought in $4.16 billion in product revenues in 2019, bolstered in large part by the late October approval of Trikafta, earning $420 million in the few weeks that remained in the year. Read More
BEIJING – The current speed of new developments in the 2019-nCov outbreak is illustrated by a Jan. 28, 2020, press conference in Munich, where Andreas Zapf, head of the infection task force in the Bavarian ministry for health and food safety, briefed reporters on the first confirmed German case. Read More
DUBLIN – The witty Twitter account @justsaysinmice, run by Northeastern University research scientist Jim Heathers, offers a very useful corrective to the misleading and unwarranted hype that often accompanies preclinical studies in mice. What looks good in murine models is all too often lost in translation, for a whole host of reasons, and never has any useful effect in patients. That’s not a concern for a group led by Thomas Thum, of the Institute of Molecular and Translational Therapeutic Strategies at Hannover Medical School in Germany, who just published in Nature Communications the outcome of what is probably the largest ever pig study in heart failure. Read More
A survey of nearly 100 biotech companies by the Biotechnology Innovation Organization (BIO) has found the industry still has important work to do before achieving overall gender parity and racial diversity, especially in executive and board roles. While showing "progress in some areas, we know that as an industry, we can do better," said Helen Torley, chair of BIO’s Workforce Development, Diversity and Inclusion (WDDI) Committee and president and CEO of Halozyme Therapeutics Inc. Read More
The EMA’s Committee for Medicinal Products for Human Use (CHMP) looked with favor on a bucketload of would-be drugs, issuing positive opinions for the European Commission to consider across a range of indications. Read More
BioWorld looks at translational medicine, including: Adapting NGS for coronavirus surveillance; Long QT genes mostly short on evidence; Reservoir dogs don’t hunt; Another reason to get a flu shot; Cerebrospinal fluid is early culprit in stroke edema; Different drivers can turn the wheel in glioblastoma’s vicious cycle; From African genomes, big insights with small sample size; Commercial antibodies underwhelm for studies of PP2A; Tau keeps gliomas in check. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aspen, Curevac, Follicum, Fuzionaire, ICER, Nanoviricides, Novartis, Predictive Oncology, Quantitative Medicine, Saromics, Vaxart, Ziopharm. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Alnylam, Bayer, Daiichi Sankyo, Emergent Biosolutions, Lilly, Novo Nordisk, Pfizer, Seattle Genetics. Read More
The top 10 biopharma stock gainers and losers for the week, including: Acceleron, Amgen, Beigene, Biontech, Cortexyme, Precision, Reata, Syndax, United, Vir. Read More
